Form 4: BridgeBio Pharma CFO Brian Stephenson Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Brian Stephenson, CFO of BridgeBio Pharma, reports the acquisition of stock options and restricted stock units.
Summary
- On March 12, 2024, Brian C. Stephenson, the Secretary, Treasurer, and CFO of BridgeBio Pharma, Inc. [BBIO], reported transactions involving the company's securities.
- Stephenson acquired 15,442 stock options with an exercise price of $28.70.
- These options vest in installments, starting with 1/16th on May 16, 2024, and then quarterly, contingent upon continued service.
- He also acquired 107,278 restricted stock units (RSUs), each representing a right to receive one share of BridgeBio's common stock.
- These RSUs also vest in installments, starting with 1/16th on May 16, 2024, and then quarterly, contingent upon continued service.
- The RSUs have no expiration date.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. It's a neutral-positive indicator.
Positives
- The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and prevent insider trading. The grants are a typical component of executive compensation packages in the biotech industry.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for compensating executives in the biotechnology industry.
- Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation plans to align executive incentives with shareholder value.
- The vesting schedules described are also typical, designed to retain key personnel over a multi-year period.
Stakeholder Impact
- Shareholders may view the grants positively as they align management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/12/2024 | Date of transaction: acquisition of stock options and RSUs. |
| 03/14/2024 | Date of signature on the Form 4 filing. |
| 05/16/2024 | First vesting date for both stock options and RSUs (1/16th). |
| 03/11/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.